Merck & Co., Inc. (MRK) Shares Sold by First Allied Advisory Services Inc.

First Allied Advisory Services Inc. trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 5.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 143,607 shares of the company’s stock after selling 9,023 shares during the quarter. First Allied Advisory Services Inc.’s holdings in Merck & Co., Inc. were worth $8,747,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in MRK. Cobblestone Capital Advisors LLC NY boosted its stake in shares of Merck & Co., Inc. by 0.4% in the 2nd quarter. Cobblestone Capital Advisors LLC NY now owns 187,080 shares of the company’s stock valued at $11,356,000 after buying an additional 774 shares during the period. Associated Banc Corp boosted its stake in shares of Merck & Co., Inc. by 0.3% in the 2nd quarter. Associated Banc Corp now owns 251,933 shares of the company’s stock valued at $15,293,000 after buying an additional 776 shares during the period. Checchi Capital Advisers LLC boosted its stake in shares of Merck & Co., Inc. by 3.0% in the 2nd quarter. Checchi Capital Advisers LLC now owns 26,914 shares of the company’s stock valued at $1,634,000 after buying an additional 792 shares during the period. Mckinley Capital Management LLC Delaware boosted its stake in shares of Merck & Co., Inc. by 5.6% in the 2nd quarter. Mckinley Capital Management LLC Delaware now owns 15,447 shares of the company’s stock valued at $938,000 after buying an additional 815 shares during the period. Finally, Brick & Kyle Associates boosted its stake in shares of Merck & Co., Inc. by 1.7% in the 2nd quarter. Brick & Kyle Associates now owns 50,020 shares of the company’s stock valued at $3,036,000 after buying an additional 830 shares during the period. Institutional investors own 72.14% of the company’s stock.

Several equities analysts have recently issued reports on MRK shares. Bank of America lifted their price objective on Merck & Co., Inc. from $70.00 to $74.00 and gave the company a “buy” rating in a research note on Monday, July 30th. Morgan Stanley set a $74.00 target price on Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Thursday, August 23rd. Jefferies Financial Group reissued a “hold” rating and set a $59.00 target price on shares of Merck & Co., Inc. in a research report on Sunday, July 15th. Zacks Investment Research raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $69.00 target price on the stock in a research report on Thursday, June 7th. Finally, SunTrust Banks reissued a “buy” rating and set a $77.00 target price on shares of Merck & Co., Inc. in a research report on Thursday, August 16th. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Merck & Co., Inc. presently has an average rating of “Buy” and a consensus price target of $68.55.

In other Merck & Co., Inc. news, Chairman Kenneth C. Frazier sold 279,851 shares of Merck & Co., Inc. stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $70.08, for a total transaction of $19,611,958.08. Following the transaction, the chairman now owns 971,801 shares of the company’s stock, valued at $68,103,814.08. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Kenneth C. Frazier sold 228,091 shares of Merck & Co., Inc. stock in a transaction that occurred on Tuesday, July 31st. The stock was sold at an average price of $65.00, for a total value of $14,825,915.00. Following the transaction, the chairman now directly owns 938,788 shares in the company, valued at approximately $61,021,220. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 649,510 shares of company stock worth $44,201,809. 0.32% of the stock is currently owned by corporate insiders.

Shares of NYSE MRK opened at $70.33 on Thursday. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.61. Merck & Co., Inc. has a fifty-two week low of $52.83 and a fifty-two week high of $71.57. The stock has a market cap of $190.84 billion, a PE ratio of 17.67, a price-to-earnings-growth ratio of 2.21 and a beta of 0.81.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, July 27th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.03. The business had revenue of $10.47 billion for the quarter, compared to analyst estimates of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the company earned $1.01 EPS. equities analysts forecast that Merck & Co., Inc. will post 4.27 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, October 5th. Shareholders of record on Monday, September 17th will be given a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a yield of 2.73%. The ex-dividend date is Friday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 48.24%.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

See Also: Dividend Aristocrat Index

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply